ISSN 2470-1343
26 papers in the library · 259 citations · publishing 2018-2026
ACS Omega July 24, 2026
Comparative Electrocorticographic Signatures of S‑Ketamine and Racemic Ketamine in the Rat Visual Cortex Across Temporal Phases.
ACS Omega June 23, 2026 Elena Bray, Grant C. Glatfelter, Alexander D. Maitland et al.
-dimethyltryptamine (DMT). Overall, the data indicate that 4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT.
ACS Omega May 13, 2026 Darío Martínez-afani, Breno A. Soares, Jaime Mella-Raipán et al. 1 citation
High Resolution Image Download MS PowerPoint Slide Serotonin 5-HT 2 receptor ligands have attracted the attention of medicinal chemists for the last half-century, first as hallucinogens and later for their antipsychotic, appetite suppressant, antiaddictive and antidepressant potential. Unlike the very potent N -benzylphenethylamine derivatives that include the abundantly studied NBOMe drugs, N...
ACS Omega March 10, 2026 Dinesh Durán Jiménez, F. Vinckenbosch, J. Busink et al.
Nitrous oxide (N2O) is commonly used as a recreational drug, and the Dutch police have reported numerous traffic incidents related to its misuse. At the same time, the in vivo pharmacokinetics of N2O remain underexplored. In light of these facts, this study aimed to detect and quantify N2O in blood and saliva after inhalation exposure of a recreational dose. Consequently, a pilot in vivo study...
ACS Omega January 7, 2026 Ana Barovic, Monica Pittiglio, Justin Barrett et al.
High Resolution Image Download MS PowerPoint Slide Novel psychoactive substances (NPS) remain an ongoing challenge for public health, forensic laboratories, and regulatory agencies, especially when they are chemically related to controlled tryptamines but are marketed as legal alternatives. In the United States, the Federal Analogue Act (FAA) was intended to restrict such substances; however,...
ACS Omega November 10, 2025 Luisina Castelli Rodríguez, Guillermo Morera, Sandra Lupo et al. 1 citation
Psychedelic mushrooms of the Psilocybe genus contain the psychoactive tryptamines psilocybin and psilocin, compounds currently under clinical investigation for the treatment of depression and other psychiatric conditions. However, the accurate quantification of these alkaloids in fungal matrices remains analytically challenging. Here, we report an optimized extraction protocol and a robust,...
ACS Omega September 16, 2025 Lucas Cordeiro de Oliveira, Taynah Pereira Galdino, Marcelo Da Silva Pedro et al. 1 citation
N,N-Dimethyltryptamine (DMT), a plant-derived tryptamine alkaloid, has attracted growing interest due to its therapeutic potential in treating mental health disorders resistant to conventional pharmacological interventions. This study aimed to establish an efficient methodology for the extraction, isolation, and characterization of DMT, and to identify the most viable portion of the Mimosa...
ACS Omega September 15, 2025 Taynah Pereira Galdino, Antônio Braz de Medeiros Bisneto, Marcelo Da Silva Pedro et al. 1 citation
High Resolution Image Download MS PowerPoint Slide Mental disorders of the global population have been evaluated statistically by decades. Psilocybin has medicinal properties with potential pharmaceutical applications for treatment of psychological disorders. This component is present naturally in mushrooms of the Psilocybe genus and is primarily responsible for their psychoactive properties....
ACS Omega August 26, 2025 Roman Boča, Juraj Štofko, Cyril Rajnák
Small molecules containing phenyl and aliphatic amine groups belonging to psychotropic drugs were studied by quantum chemical computational methods. Each of the 9 studied species (phenethylamine, amphetamine, ephedrine, pseudoephedrine, methamphetamine, MDMA, MDEA, MDA, MDAI) was considered in three oxidation states: neutral molecule, molecular cation, and molecular anion. Protonated residues...
ACS Omega July 10, 2025 Taynah Pereira Galdino, Lucas C Oliveira, Mateus A Luz et al. 5 citations
Innovative therapies, such as psilocybin-assisted psychotherapies, hold great promises for treating anxiety, depression, and various other mental health disorders, addressing some of the challenges faced by conventional psychiatric medicine. This study focuses on developing and validating an HPLC-DAD methodology for detecting psilocybin and psilocin in extracts from psychedelic mushrooms...
ACS Omega April 29, 2025 Cláudia Mancilha Rocha, Larissa Magalhães de Almeida Melo, Augusto César Carvalho Santos et al. 5 citations
Lysergic acid diethylamide (LSD) and phenylethylamine derivatives (NBOHs and NBOMes) are commonly found on seized blotter papers, posing public health risks. Efficient screening methods for identifying these substances are currently limited. To address this, a novel protocol combining colorimetric and electrochemical techniques was developed as a screening method for drugs of abuse in blotter...
ACS Omega September 24, 2024 Ana Y Martínez, Alexis Caballero, Rodrigo Ramírez et al.
Psychedelics are psychoactive substances that produce changes in thoughts and feelings and modifications in perceptions of reality. The most potent psychedelic is also the first semisynthetic hallucinogen (lysergic acid diethylamide). Psychedelics have been investigated for decades because of their potential therapeutic effects in the treatment of neuropsychiatric diseases and also because...
ACS Omega August 27, 2024 Marcelo N. Costa, Livia Goto-Silva, Juliana Nascimento et al. 3 citations
Proteomic analysis of human cerebral organoids may reveal how psychedelics regulate biological processes, shedding light on drug-induced changes in the brain. This study elucidates the proteomic alterations induced by lysergic acid diethylamide (LSD) in human cerebral organoids. By employing high-resolution mass spectrometry-based proteomics, we quantitatively analyzed the differential...
ACS Omega January 10, 2023 Megan I. Chambers, Justine E Giffen-Lemieux, Rabi A. Musah 5 citations
In recent years, national laboratories have identified several plant-derived materials as concerns to public health because of their psychoactive effects, potential for abuse, and the lack of federal regulation of their use. One of these is Salvia divinorum (aka Salvia), which has received focused attention due to its increasing recreational use and the ease by which it can be acquired....
ACS Omega July 5, 2022 Grant C. Glatfelter, Duyen N. K. Pham, Donna Walther et al. 14 citations
Aeruginascin (4-phosphoryloxy-N,N,N-trimethyltryptammonium) is an analogue of psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) that has been identified in several species of psilocybin-containing mushrooms. Our team previously reported the synthesis, structural characterization, and biological activity of the putative metabolite of aeruginascin (4-hydroxy-N,N,N-trimethyltryptammonium;...
ACS Omega April 1, 2022 Luisina Castelli Rodríguez, Andrés Mariño López, Guillermo Moyna et al. 28 citations
Ayahuasca is a psychedelic beverage originally from the Amazon rainforest used in different shamanic settings for medicinal, spiritual, and cultural purposes. It is prepared by boiling in water an admixture of the Amazonian vine Banisteriopsis caapi, which is a source of β-carboline alkaloids, with plants containing N,N-dimethyltryptamine, usually Psychotria viridis. While previous studies have...
ACS Omega February 7, 2022 Robert B. Kargbo, Alexander M. Sherwood, Poncho Meisenheimer et al. 5 citations
Psilocybin, a serotonergic agonist, was granted a "breakthrough therapy" status by the Food and Drug Administration for clinical trials involving major depressive disorder and treatment-resistant depression. The direct phosphorylation of psilocin to psilocybin that uses a fast crystallization associated with a kinetically controlled process resulted in a smaller particle size distribution....
ACS Omega December 20, 2021 Jay B. Nair, Linda B Hakes, Berra Yazar-Klosinski et al. 12 citations
MDMA is increasingly used in clinical research, but no cGMP process has yet been reported. We describe here the first fully validated cGMP synthesis of up to 5 kg (≈30 000 patient doses) of MDMA in a four-step process beginning with a noncontrolled starting material. The overall yield was acceptable (41-53%, over four steps), and the chemical purity of the final product was excellent, exceeding...
ACS Omega July 6, 2021 Bruno González, Catherine Fagúndez, Alejandro Peixoto de Abreu Lima et al. 18 citations
Iboga alkaloids are a group of monoterpenoid indole alkaloids with promising and intriguing biological activities. Ibogaine is the representative member of the series and has become widely known as a potent atypical psychedelic with promising effects to treat substance use disorder. Nowadays, an efficient and scalable enantioselective total synthesis of ibogaine and related iboga alkaloids is...
ACS Omega December 2, 2020 Alexander M. Sherwood, Romain Claveau, Rafael Lancelotta et al. 38 citations
To support clinical use, a multigram-scale process has been developed to provide 5-MeO-DMT, a psychedelic natural product found in the parotid gland secretions of the toad, Incilius alvarius. Several synthetic routes were initially explored, and the selected process featured an optimized Fischer indole reaction to 5-MeO-DMT freebase in high-yield, from which the 1:1 succinate salt was produced...
ACS Omega October 27, 2020 Megan I. Chambers, Meghan G. Appley, Cameron M. Longo et al. 17 citations
The United Nations Office on Drugs and Crime designated twenty psychoactive botanical species as "plants of concern" because of their increased recreational abuse. Four of these are used to prepare ayahuasca brews. The complexity of the plant matrices, as well as the beverage itself, make the identification and quantification of the Schedule I component, N,N-dimethyltryptamine (DMT), a...
ACS Omega July 2, 2020 Andrew R Chadeayne, Duyen N. K. Pham, Brian G. Reid et al. 31 citations
The putative active metabolite of aeruginascin, a naturally occurring tryptamine of "magic mushrooms," has been synthesized and structurally characterized. Competitive radioligand binding assays demonstrate that it has a high affinity at human serotonin receptors 5-HT1A, 5-HT2A, and 5-HT2B, though it does not bind at the 5-HT3 receptor, where activity was previously predicted.
ACS Omega July 1, 2020 Jessica Sable, Tura Patterson, Gary Tarpley et al. 41 citations
A second-generation kilogram-scale synthesis of the psychedelic tryptamine psilocybin has been developed. The synthesis was designed to address several challenges first encountered with the scale-up of previously described literature procedures, which were not optimized for providing consistent yield and purity of products, atom economy, or being run in pilot plant-scale reactors. These...
ACS Omega September 24, 2019 Meghan Grace Appley, Samira Beyramysoltan, Rabi Ann Musah 18 citations
The United Nations Office on Drugs and Crime has designated several "legal highs" as "plants of concern" because of the dangers associated with their increasing recreational abuse. Routine identification of these products is hampered by the difficulty in distinguishing them from innocuous plant materials such as foods, herbs, and spices. It is demonstrated here that several of these products...
ACS Omega August 29, 2019 H. Elbardisy, Christopher W. Foster, Jack Marron et al.
The emergence of a new class of novel psychoactive substances, N-benzyl-substituted phenethylamine derivatives so-called “NBOMes” or “Smiles”, in the recreational drug market has forced the development of new sensitive analytical methodologies for their detection and quantitation. NBOMes’ hallucinogenic effects mimic those of the illegal psychedelic drug lysergic acid diethylamide (LSD) and are...